ArticleOncology letters2025
Six-year survival after oral temozolomide maintenance therapy in limited-stage small cell lung cancer: A case report.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small cell lung cancer (SCLC) accounts for 13-17% of lung cancer cases and is characterized by poor differentiation, high malignancy and a propensity for recurrence and metastasis. Limited-stage SCLC (LS-SCLC) typically has a better prognosis than extensive-stage SCLC due to its localized nature. However, even with standard concurrent chemoradiotherapy, the median overall survival (OS) for LS-SCLC is only 30 months, with a 5-year survival rate of merely 29-34%. The present study reported the case a patient with LS-SCLC who received oral temozolomide (TMZ) maintenance therapy, achieving an impressive 6-year survival without disease progression or significant side effects. Factors contributing to this outcome include the cytotoxic effects of TMZ and its potential preventive and therapeutic roles in managing brain metastases. In addition, durvalumab has been proven to prolong OS as maintenance therapy after first-line chemoradiotherapy in patients with LS-SCLC. In the future, maintenance therapy for SCLC should explore combination drug strategies, as integrating TMZ or poly(ADP-ribose) polymerase inhibitors with immunotherapy may enhance patient survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.